Extraordinary General Meeting of shareholders in CombiGene AB (publ) 2018

An extraordinary general meeting of shareholders in CombiGene AB (publ) was held today, 18 October 2018. Resolutions approved by the meeting are summarized below.

Approval of the Board’s resolution regarding a rights issue

The Board decided on 22 August 2018 to introduce a new issue of so-called units, consisting of shares and warrants, with preferential rights for shareholders. The new issue of shares was supported by authorization of the Annual General Meeting, while the new issue of warrants was contingent upon approval by today’s extraordinary general meeting of shareholders.

The meeting approved the board’s resolution on a preference issue of at most 6,879,130 warrants of series 2018/2019, each of which entitles the holder to subscribe for one share in the company. Warrants are free of charge. The company’s share capital may increase by at most 687,913 kronor and the number of shares may increase by at most 6,879,130 shares if all warrants of series 2018/2019 are utilized.

CombiGene AB (publ)
Jan Nilsson, VD
Tel: +46 (0)704 66 31 63
jan.nilsson@combigene.com

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Spotlight. www.combigene.com